[Chemotherapy of neuroendocrine tumors].
Chemotherapy has few impact on neuroendocrine tumour patients outcome: it may decrease functional secretory symptoms and increase slightly median survival time. In islet-cell carcinoma of the pancreas the standard chemotherapy regimen is the combination of streptozotocin and doxorubicin. It induces 50% response rate and may increase by 50% the median survival. In enterochromaffin-cell tumours chemotherapy has modest impact and the combination of 5-fluorouracile and streptozotocin is the standard regimen. In undifferentiated enterochromaffin-cell tumours of unknown primary the standard chemotherapy regimen is the combination of etoposide and cisplatin which induces 50% response rate with probably no impact on overall survival. Chemotherapy must be indicated within the frame of a multidisciplinary approach and only in patients who have refractory and progressive disease. Indication of chemotherapy must be balanced with indications of biotherapies and embolization.
Droz
Jean-Pierre
JP
Département de cancérologie médicale Centre Léon-Bérard 69373 Lyon. droz@lyon.fnclcc.fr
Flechon
Aude
A
Lombard-Bohas
Catherine
C
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D013311:Streptozocin / Q000008:administration & dosage; D016019:Survival Analysis
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D013311:Streptozocin; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin
Chimiothérapie des tumeurs neuro-endocrines.